Form D to Follow: Sermonix Pharmaceuticals $2.50 million Fundraising. David Portman Submitted Jul 11 D form


Pharmaceuticals Sermonix Pharmaceuticals, Llc - David Portman

Sermonix Pharmaceuticals Financing

Sermonix Pharmaceuticals, Llc, Limited Liability Company just released form D announcing $2.50 million equity financing. This is a new filing. Sermonix Pharmaceuticals was able to finance itself with $1.55 million so far. That is 62.00% of the fundraising. The total fundraising amount was $2.50 million. This form was filed on 2016-07-11. The reason for the financing was: unspecified. The fundraising still has about $950,000 more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Sermonix Pharmaceuticals is based in Ohio. The company’s business is Pharmaceuticals. The form was submitted by David Portman Chief Executive Officer. The company was incorporated in 2014. The filler’s address is: 99 North Brice Road, Suite 120, Columbus, Oh, Ohio, 43213. David Portman is the related person in the form and it has address: 99 North Brice Road, Suite 120, Columbus, Oh, Ohio, 43213. Link to Sermonix Pharmaceuticals Filing: 000165556616000003.

Analysis of Sermonix Pharmaceuticals Offering

On average, startups in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Sermonix Pharmaceuticals sold 62.00% of the offering. The fundraising is still open. Could this mean that the trust in Sermonix Pharmaceuticals is high? The average investment offering size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 178.78% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this offering is set at $25000. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Sermonix Pharmaceuticals Also

The Form D signed by David Portman might help Sermonix Pharmaceuticals, Llc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply